Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

NCT03234153 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped low accrual

Conditions

Muscle-invasive Bladder Cancer

Interventions

DRUG: Durvalumab (Imfinzi)
DRUG: Tremelimumab

Sponsor

Insel Gruppe AG, University Hospital Bern

Collaborators

[object Object]